NCT00041483View on ClinicalTrials.gov

Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD

PHASE3CompletedINTERVENTIONAL
Enrollment

530

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
Macular Degeneration
Interventions
DRUG

Anecortave Acetate 15 mg sterile suspension

OTHER

Photodynamic Therapy (PDT)

Trial Locations (1)

76134

Contact Alcon Call Center for Trial Locations, Fort Worth

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT00041483 - Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD | Biotech Hunter | Biotech Hunter